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Abstract
Cell-to-cell transmission of vaccinia virus can be mediated by enveloped virions that remain attached to the outer surface of
the cell or those released into the medium. During egress, the outer membrane of the double-enveloped virus fuses with
the plasma membrane leaving extracellular virus attached to the cell surface via viral envelope proteins. Here we report that
F-actin nucleation by the viral protein A36 promotes the disengagement of virus attachment and release of enveloped virus.
Cells infected with the A36YdF virus, which has mutations at two critical tyrosine residues abrogating localised actin
nucleation, displayed a 10-fold reduction in virus release. We examined A36YdF infected cells by transmission electron
microscopy and observed that during release, virus appeared trapped in small invaginations at the plasma membrane. To
further characterise the mechanism by which actin nucleation drives the dissociation of enveloped virus from the cell
surface, we examined recombinant viruses by super-resolution microscopy. Fluorescently-tagged A36 was visualised at sub-
viral resolution to image cell-virus attachment in mutant and parental backgrounds. We confirmed that A36YdF extracellular
virus remained closely associated to the plasma membrane in small membrane pits. Virus-induced actin nucleation reduced
the extent of association, thereby promoting the untethering of virus from the cell surface. Virus release can be enhanced
via a point mutation in the luminal region of B5 (P189S), another virus envelope protein. We found that the B5P189S
mutation led to reduced contact between extracellular virus and the host membrane during release, even in the absence of
virus-induced actin nucleation. Our results posit that during release virus is tightly tethered to the host cell through
interactions mediated by viral envelope proteins. Untethering of virus into the surrounding extracellular space requires
these interactions be relieved, either through the force of actin nucleation or by mutations in luminal proteins that weaken
these interactions.
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Introduction
Crossing the membrane of host cells, either during entry or
escape, is a major obstacle facing prospective viral pathogens
during infection. Enveloped viruses are released from cells by
either the acquisition or loss of an outer membrane and both
strategies pose unique challenges to the final separation of
pathogen from host. Where viruses gain a membrane, for example
influenza virus and human immunodeficiency virus, a tight
association must be formed between assembling viral complexes
and the internal surface of the cell membrane that is loaded with
viral envelope proteins [1,2]. As the budding virus emerges into
the extracellular space, membrane scission must take place, an
energetically difficult event [3]. Other viruses, including herpes
simplex virus, acquire a double membrane during morphogenesis
that is tightly complexed by viral protein interactions across the
luminal space [4]. Upon reaching the cell surface, an exocytotic
membrane fusion event is followed by the peeling away of the
outer vesicle membrane accompanied by the disengagement of
virus–cell associations. Mature enveloped virions are then free to
diffuse in the extracellular space. The release of extracellular
enveloped virus (EEV), the morphological variant implicated in
cell-to-cell transmission of vaccinia virus (VACV), operates
through a membrane-loss mechanism. Intracellular enveloped
viruses (IEV) arrive at the plasma membrane where the outer of
two early endosome or trans-Golgi derived membranes fuses with
the plasma membrane forming cell-associated enveloped virus
(CEV) [reviewed in 5]. Extracellular CEV remain associated with
host cells and this attachment is likely to be mediated by viral
envelope proteins [6,7,8]. For example, the viral proteins B5, A33
and A34 (encoded by the B5R, A33R and A34R genes,
respectively) contain significant luminal regions [9,10,11,12]. In
support of a role for these luminal domains in virus–host cell
adhesion, a number of mutations in these proteins have been
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documented that lead to increased EEV release (B5P189S,
A34K151E and a C-terminal deletion in A33) [6,13,14]. While
CEV are able to maintain a tight affinity to the surface of infected
cells, over time they are untethered and free to access the
extracellular space, though how the affinity is regulated remains
largely unknown. A number of lines of evidence demonstrate that
host-signalling pathways affect the dissociation of VACV. For
example, cell lines of different origin display significantly altered
kinetics of EEV release that is independent of the total amount of
virus made [15]. Inhibition of epidermal growth factor receptor
reduces EEV from VACV IHD-J strain [16]. Finally, EEV levels
are reduced in the absence of the phosphoinositide 5-phosphatase
SHIP2 [17]. These data further support the hypothesis that the
generation of enveloped virus and the untethering of enveloped
virus are regulated independently. Inhibition of Abl tyrosine
kinases also results in reduced EEV [18,19], although at this stage
it is unclear as to whether this is a specific defect in EEV
dissociation or a more general defect in virus morphogenesis.
The viral transmembrane protein A36 is currently the only Abl
substrate that has been implicated in VACV morphogenesis,
although its role in Abl-mediated release is unknown [18,19,20].
Of the integral viral proteins localised to IEV, A36 is unusual in
that it is expressed exclusively in the outer of the two trans-Golgi-
derived membranes [21,22]. Consequently, it is present beneath
CEV once the outer virus membrane fuses and becomes
contiguous with the plasma membrane, and accordingly is absent
from released EEV. Unlike B5, A33 and A34, the bulk of the A36
protein extends into the cytoplasm. Here it mediates interactions
with the microtubule cytoskeleton via WE/WD motifs [23,24,25],
and the actin cytoskeleton via the phosphorylation of tyrosine
residues at positions 112 and 132 (A36Y112, A36Y132 respectively)
[26,27,28]. Src- and Abl-family kinases instigate the phosphory-
lation of A36Y112 and A36Y132, which generates binding sites for
the SH2 domains of Nck and Grb2 adaptor proteins that combine
to stabilise N-WASP, a potent activator of the Arp2/3 complex
[20,26,28,29,30]. Activation of the F-actin branching activity of
the Arp2/3 complex beneath CEV promotes virus motility that is
restricted to the plane of the cell membrane and results in thin
virus-tipped membrane protrusions. Although Src- and Abl-family
kinases act redundantly to phosphorylate A36 [19,20], inhibition
of Abl-family kinases alone with the specific inhibitor imatinib
results in reduced EEV release without affecting actin nucleation
[19,31]. Localised actin nucleation expedites the dispersal of CEV
to neighbouring cells and also facilitates super-repulsion, which
has been proposed to account for the rapid cell-to-cell transmission
of virus that outpaces replication dynamics [32]. Super-repulsion
occurs when either CEV or EEV contact the surface of early-
infected cells, are repelled by A36-induced actin-based motility
and leapfrog to uninfected cells. This process is dependent on
early-stage expression of A36 in the recipient cell membrane,
before infectious progeny are produced.
Here we show that introducing both Y112F and Y132F
mutations into A36 leads to a severe decrease in the production
of EEV. In the absence of virus-induced actin nucleation, virus
particles remained trapped at the plasma membrane in small
invaginations.
When parental VACV was examined using three-dimensional
structured illumination microscopy (3D-SIM), it was found that
upon reaching the surface, A36 redistributed to a discrete region
beneath CEV, reducing contact between extracellular virus and the
host cell. This redistribution was dependent on actin-based motility
but could also be phenocopied by a mutation in the luminal domain
of the envelope protein B5. In our model, following the fusion of
IEV at the plasma membrane, CEV remain tethered to the cell in
tight membrane pits through interactions between viral proteins.
Tethering can be relieved either by mutations in the luminal
domains of viral proteins that disrupt these interactions, or by the
force supplied by localised actin nucleation.
Results
A36 Y112 and Y132 play an essential role in EEV release
Actin-based motility appears to have evolved independently in a
diverse range of pathogenic bacteria and viruses, and it is speculated
to contribute to virulence in a context-specific manner [33,34]. To
better understand the role of pathogen-induced actin nucleation in
the replication and spread of VACV, we tested the effects of
blocking the phosphorylation of A36Y112 and A36Y132 on the release
of EEV. These residues are critical to the canonical pathway
whereby VACV induces actin nucleation by recruitment and
activation of the Arp2/3 complex. Plaque assays performed under
semi-solid overlay are used to quantitate replication dynamics and
cell-to-cell transmission. When performed under a liquid overlay,
these are termed ‘comet’ assays and the efficiency of EEV release
can be qualitatively assessed by the formation of satellite plaques
that disperse from primary plaques due to the action of convection
currents [6,35]. Plaque assays were performed in BSC-1 cells with
VACVWestern Reserve (WR, parental strain), A36Y112F, A36Y132F
and A36YdF ( =A36Y112F/Y132F) to assess cell-to-cell spread
(Figure 1A). The A36YdF virus yielded plaques significantly smaller
than WR, in broad agreement with previous reports [36]. Mutation
of Y112 alone also had a significant effect on plaque size whereas
mutation of Y132 alone resulted in plaques not significantly
different to those of WR (Figure 1B). Similar results were observed
when using NIH3T3 cells (Figure 1C). Reduction in plaque size is
likely to be due to the loss of actin-based motility, potentially by its
role in facilitating cell-to-cell spread by super-repulsion [32]. A36YdF
and A36Y112F viruses do not activate the Nck pathway, which is
both necessary and sufficient for actin-based motility, whereas
mutation of Y132 leads to a disruption in the dynamics of N-WASP
recruitment and a reduction in the efficiency of the initiation of
actin-based motility [26,28].
We next subjected the A36 mutant strains to comet assays to
assess EEV release. A reduction in the extent of comet formation
was observed in all strains carrying Y/F substitutions (Figure 1A).
Author Summary
Traversing the plasma membrane of the host cell is a
significant challenge for many viruses during the infection
cycle, and the efficiency of detachment from the host cell
and subsequent release can have implications in patho-
genesis. Vaccinia virus exits cells through the loss of an
outer membrane but remains attached via viral envelope
proteins that mediate adhesion between the cell and virus.
Here we report that actin filament nucleation by the viral
protein A36 promotes the disengagement of virus attach-
ment. Viruses unable to locally induce actin nucleation
displayed significantly reduced release and particles were
found trapped in small pits at the plasma membrane.
Mutations in luminal viral proteins that disrupt attachment
identified an alternative route to virus release, bypassing
the requirement for actin nucleation. Our results suggest
that untethering virus attachment to the cell surface is a
rate-limiting step during exocytic release of vaccinia virus.
We have elucidated that the force of actin nucleation is the
primary mechanism that operates to relieve these interac-
tions.
Actin Nucleation Promotes Vaccinia Virus Release
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Figure 1. Plaque size and release of VACV is inhibited by mutation of Y112 and Y132 residues in A36. (A) BSC-1 cells were infected with
the indicated viruses, incubated with a semi-solid (plaque assay, 1.5% CMC) or liquid (comet assay, DMEM) overlay, with either imatinib or carrier
(DMSO), stained at 72 hpi. (B) Average plaque size of WR, A36Y112F, A36Y132F and A36YdF in BSC-1 or (C) NIH 3T3 cells. Error bars represent s.e.m. from
Actin Nucleation Promotes Vaccinia Virus Release
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The greatest reduction was observed in cells infected with A36YdF,
followed by A36Y112F, and only a minor reduction was seen with
A36Y132F. To support these findings and quantify the effects of
A36 phosphorylation on virus release, EEV release assays were
performed in BSC-1 cells. We observed the same trend in EEV
release as in the comet assays, with the greatest inhibition of
release (approximately 10-fold) seen with A36YdF and a significant
inhibition seen when Y112 was mutated (Figure 1E). These
findings were replicated when release assays were performed in
NIH3T3 cells (Figure 1F). Disruption of A36 does not result in
early defects in wrapping and morphogenesis and the Y112 and
Y132 residues are not required for microtubule-dependent
delivery of IEV to the cell surface [21,23,24,37,38,39]. Single-
step growth curves did not reveal significant differences in the
replication dynamics between WR, A36Y112F, A36Y132F and
A36YdF (Figure 1D). Thus, any differences observed in EEV
release for these viruses cannot be accounted for by earlier
morphogenesis or transport defects.
Abl kinases regulate at least two distinct steps during VACV
replication: EEV release and actin-based motility of CEV, in the
latter case through A36 phosphorylation [19,20]. The effects of
abrogating release by mutation of Y112 or Y132 are consistent
with A36 fulfilling the role as the Abl-dependent mediator of virus
release. To test this role, we examined the effects of imatinib in our
various mutant backgrounds. Imatinib is a kinase inhibitor that
blocks the ATP binding site on Abl-family kinases and has
remarkable specificity displaying no detectable activity against Src-
family kinases [20,31]. Surprisingly, we found that regardless of
the integrity of A36 residues Y112 and Y132, treatment with
imatinib led to a significant reduction in comet formation and an
approximately 2- to 3-fold decrease in EEV (Figure 1A, 1E, 1F).
These results demonstrate a role for A36 tyrosine phosphorylation
in release that is independent of the effects of imatinib. Although
we cannot exclude that Abl kinases regulate virus release via A36
phosphorylation, if they do so they act redundantly with Src-family
kinases, as they do in the initiation of actin-based motility.
A second site mutation in B5 restores EEV release
independently of A36 Tyr substitutions
Deletion of genes encoding envelope-specific proteins can
increase (A33R, A34R) or decrease (B5R, F13L) production of
EEV, often due to earlier defects in morphogenesis [40,41,42,43].
While our results are the first to implicate A36 tyrosine
phosphorylation in virus release, it has previously been shown
that deletion of A36 results in a dramatic reduction in EEV [37].
This is unsurprising given the essential role this protein plays in
delivering IEV to the cell surface through kinesin-1 based
transport; however, Y112 and Y132 play no part in this process
[23,24,25]. Inhibition of virus release in an A36 deletion strain can
be derepressed, and significantly enhanced, by second-site
mutations in genes that encode the envelope-specific proteins B5
(P189S substitution) and A33 (C-terminal truncations) [14]. A
point mutation in A34R (K151E), identified in the IHD-J strain,
also significantly enhances EEV release in a WR background
[6,19]. We tested whether the B5P189S or A34K151E alleles would
also promote EEV release in an A36YdF background. Both B5P189S
and A34K151E led to substantial increases in comet formation both
in a parental and A36YdF background (Figure 2A). EEV release
assays revealed that the B5P189S virus generated 5-fold more
infectious EEV than the parental WR strain and 40-fold more
than A36YdF (Figure 2B). There was no significant difference in
EEV release between B5P189S in a WR background or an A36YdF
background. The A34K151E virus produced 50-fold more infec-
tious EEV than WR and 400-fold more than A36YdF (Figure 2B).
In contrast to the B5P189S virus, a significant reduction (10-fold) in
EEV was observed in A34K151E/A36YdF virus compared to
A34K151E (Figure 2B). Therefore, in a background where actin-
based motility is intact (WR and A34K151E) [17,44], the A36YdF
mutation potently supresses EEV release. Conversely, in a B5P189S
background, which is strongly deficient in actin-based motility
owing to a failure of kinase activation, the A36YdF allele has no
effect on EEV release [30].
Inhibition of virus-induced actin nucleation results in
defects in EEV release
Our results indicate that phosphorylation of A36 is required for
efficient EEV release but do not discriminate whether this is due to
the induction of localised actin polymerisation or signalling via
A36 through another mechanism. We therefore tested the effects
of inhibiting actin nucleation on EEV production using two
different approaches. Nck-null mouse embryonic fibroblasts do not
support virus-associated actin nucleation due to the essential
requirement of this adaptor protein in the recruitment of N-WASP
and subsequent activation of the Arp2/3 complex [26,28,45].
Nck-null cells infected with WR or A36YdF released similar levels
of EEV (Figure 3A). Nck-null cells infected with B5P189S, B5P189S/
A36YdF, A34K151E and A34K151E/A36YdFexhibited similar levels
of EEV release, approximately 3-fold greater than WR and
A36YdF. We further tested the role of virus-induced actin
nucleation by treating infected cells with cytochalasin D (Cyt D),
a potent inhibitor of actin polymerisation that caps the fast
growing ends of actin filaments. Previous studies have shown that
Cyt D significantly reduces WR EEV while having little effect on
morphogenesis or formation of CEV [15,39,46]. Treatment with
Cyt D resulted in a 3-fold reduction in EEV release from cells
infected with WR or A34K151E (Figure 3B). In contrast, Cyt D had
little impact on EEV production in cells infected with A36YdF or
B5P189S. Collectively, these data suggest that in the absence of
virus-induced actin nucleation, the release of EEV is independent
of the status of A36 Y112 and Y132 residues. Hence, the
deficiency in EEV release observed for A36YdF can be replicated
by Cyt D treatment, and in a cell line where actin-based motility is
blocked, inhibition of EEV release due to the YdF mutation is not
observed.
A36Y112F induces localised F-actin accumulation
Our results show a correlation between actin-based motility and
release of EEV, with one anomaly. The A36Y112F virus displays a
small, but significant, increase in virus release compared to A36YdF
(Figure 1E, 1F), yet both strains have been characterised as
deficient in actin-based motility [26]. To resolve this paradox, we
re-examined A36Y112F-infected cells and compared these with
WR- and A36YdF-infected cells. Consistent with previous reports
we were unable to detect virus-associated F-actin tails of 3–4 mm
50 plaques. (D) Single-step growth analysis of VACV strains. Monolayers of BSC-1 cells were infected with the indicated viruses at a MOI of 5. At 4, 8,
12 and 24 hpi cells and supernatants were harvested and virus titres were determined by titration with BSC-1s. The average titres of two independent
experiments are plotted at each time point. (E) Levels of infectious EEV in supernatants collected 16 hpi from BSC-1 cells or (F) NIH3T3 cells infected
at an MOI of 0.1 and overlayed with DMEM containing 0.01% DMSO (unfilled) or 10 mM imatinib (filled). Error bars represent s.e.m. from 3 replicate
wells in 3 independent experiments. P values of ,0.05, ,0.01 and ,0.001 are represented by *, ** and ***, respectively.
doi:10.1371/journal.ppat.1003239.g001
Actin Nucleation Promotes Vaccinia Virus Release
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in length, which are typical of WR infection, in A36Y112F-infected
cells (Figure 3C) [28]. However, we did observe F-actin
accumulations that colocalised with extracellular A36Y112F virus,
albeit infrequently. Small clumps of F-actin accumulation are
observed in VACV-infected and uninfected cells at a low
frequency, so to determine whether the observed colocalisations
were stochastic events or represented viral-induced actin nucle-
ation, we imaged cells with live microscopy (Figure 3D and Video
S1, S2, S3). In cells infected with A36YdF (n = 9), no motile virus
particles were associated with F-actin. In cells infected with
A36Y112F (n = 9), six cells had at least one example of virus motility
associated with transient F-actin accumulation over the course of
two minutes. This was in contrast to actin tails that were associated
with parental WR virus, which were robust and longer lived
(Figure 3D). Taken together, these results confirm a correspon-
dence between the ability to stimulate actin nucleation, albeit
weakly in the case of A36Y112F, and defects in EEV release.
A36YdF enveloped virus localises to pits at the plasma
membrane
In order to disclose the mechanism by which EEV release is
disrupted in A36YdF, we examined infected cells by transmission
electron microscopy (TEM). The majority of exiting enveloped
viruses were found loosely associated with the plasma membrane
in WR infected cells (Figure 4A), whereas A36YdF viruses were
predominantly contained in membrane pits at the surface of
infected cells (Figure 4B). A36YdF viruses that remained at the cell
surface were identified as CEV as the outer viral membrane was
observed to be contiguous with the plasma membrane [47,48].
The proportion of the CEV envelope in contact with the cell
membrane was measured and was found to be significantly
different between WR and A36YdF. A36YdF CEV displayed greater
contact on average with the host membrane than the parental
strain (Figure 4C). CEV residing in plasma membrane pits have
been previously documented when cells infected with IHD-J, a
strain harbouring the A34K151E substitution, were treated with Cyt
D (see Figure 4A in [15]). These results suggested that virus-
induced actin nucleation might function to expel CEV from
membrane pits leading to release of EEV.
A36 redistribution upon virus exit is inhibited in the
absence of actin nucleation
Despite the high resolution afforded by TEM, the extremely
small portion of the total cell volume that is included in an
ultrathin section does not provide sufficient data for extensive
quantitative comparisons between strains. Fluorescence microsco-
py of fluorescently-tagged or immunolabelled proteins is a more
efficient way to visualise protein localisation and this approach is
also amenable to labelling of non-permeabilised cells to distinguish
extracellular epitopes. Standard wide-field or confocal imaging is,
Figure 2. A second site mutation in B5 restores EEV release in A36YdF. (A) Plaque (semi-solid overlay) and comet (liquid overlay) assays of
A36YdF, B5P189S, B5P189S/A36YdF, A34K151E or A34K151E/A36YdF stained at 72 hpi. (B) Levels of infectious EEV in supernatants collected at 16 hpi from
BSC-1 cells infected at an MOI of 0.1. Error bars represent s.e.m. from 3 replicate wells in 3 independent experiments. P values of,0.05 and,0.01 are
represented by * and **, respectively.
doi:10.1371/journal.ppat.1003239.g002
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Figure 3. Actin polymerisation is required for efficient EEV release. Infectious EEV levels in supernatant collected at 16 hpi from (A) Nck-null
cells infected with WR, A36YdF B5P189S, B5P189S/A36YdF, A34K151E or A34K151E/A36YdF at an MOI of 0.1; (B) BSC-1 cells infected with WR, A36YdF, B5P189S
or A34K151E at an MOI of 0.1 and overlayed with DMEM containing 0.01% DMSO (unfilled) or 0.1 mg/ml Cyt D (filled). Error bars represent s.e.m. from 3
replicate wells in 3 independent experiments. P values of ,0.01 and ,0.001 are represented by ** and ***, respectively. (C) Fluorescent micrographs
of HeLa cells infected with WR, A36Y112F and A36YdF. Robust F-actin comets are associated with WR and localised accumulation of actin is observed
sporadically with A36Y112F (insets). Extracellular virus is detected with B5 antibody (red, non-permeabilised cells) and actin with phalloidin (green).
Scale bar = 10 mm. (D) Confocal micrographs of HeLa cells infected with B5-YFP, A36Y112F/B5-YFP and A36YdF/B5-YFP and expressing Lifeact-mRFP.
Distinct F-actin comets are associated with both B5-YFP and A36Y112F/B5-YFP, while colocalisation between F-actin and A36YdF/B5-YFP occurs
stochastically as viruses move over previously existent F-actin structures. Scale bar = 3 mm.
doi:10.1371/journal.ppat.1003239.g003
Figure 4. A36YdF is invaginated at the cell membrane during egress. Representative transmission electron micrographs of BSC-1 cells
infected with (A) WR and (B) A36YdF at an MOI of 5 and fixed at 9 hpi. In contrast to WR, distinct membrane pits containing virus are apparent during
A36YdF virus egress. Scale bar = 0.2 mm. (C) Average percentage of viral membrane circumference in contact with cell membrane calculated from 14
(WR) or 16 (YdF) viruses randomly selected from the transmission electron micrographs. *** = P value of ,0.001.
doi:10.1371/journal.ppat.1003239.g004
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however, limited by the diffraction of light that poses a limit on
resolving power to approximately 250 nm. To exploit the
advantages of fluorescence microscopy and simultaneously resolve
virus particle morphology we utilised 3D-SIM super-resolution
microscopy [49]. We generated recombinant viruses that inserted
A36-YFP or A36YdF-YFP into the endogenous locus; these were
subsequently combined with B5P189S, A34K151E and B5-mRFP
(monomeric red fluorescent protein) alleles or transgenes. Initially,
cells expressing Lifeact fused to cerulean fluorescent protein (to
visualise the actin cytoskeleton) were infected with A36-YFP/B5-
mRFP virus. Lifeact is a 17 amino acid peptide that binds to
filamentous actin [50]. Using 3D-SIM, envelope proteins A36 and
B5 resolved as hollow spherical structures that corresponded to
IEV [data not shown and 51]. When A36 was localised to virus-
tipped F-actin tails, a redistribution was apparent as A36
concentrated to discrete regions adjacent to the virus particles,
whereas B5 remained distributed along the circumference of virus
particles (Figure 5A). This is consistent with previous electron
microscopy studies which have demonstrated that unlike B5, A36
is excluded from the inner of the two trans-Golgi derived viral
membranes [22]. To further support our electron microscopy
data, we compared the localisation of A36-YFP with A36YdF-YFP,
while distinguishing between extracellular and intracellular
enveloped virus with an antibody label (Figure 5B, 5C, 6C). We
were able to observe a trend of A36-YFP polar redistribution upon
fusion with the plasma membrane that was inhibited in the A36YdF
background. Thus, in the absence of A36 tyrosine phosphorylation
and actin nucleation, close contact is maintained between
extracellular virus (labelled with anti-B5) and the surface of the
cell (labelled with A36-YFP). Analysis of individual z-planes in a
3D reconstruction revealed contact between the virus and cell was
limited to a few planes in A36-YFP, but in A36YdF-YFP A36
colocalised with exposed B5 over the majority of a CEV particle
(Figure 6C), reflecting the TEM phenotype. A36 was frequently
polarised at the surface of both B5P189S/A36-YFP and B5P189S/
A36YdF-YFP enveloped virus (Figure 5D). Thus introduction of the
B5P189S allele restored A36 polarisation in a YdF background. In
contrast, the polarisation of A36 in A34K151E/A36-YFP was
inhibited by the YdF mutation (Figure 5D). These data were
quantified by enumerating single viruses that corresponded to
categories of close, intermediate and loose contact (polar,
intermediate and circular A36 distributions). This analysis
revealed the majority of A36-YFP, B5P189S/A36-YFP, B5P189S/
A36YdF-YFP and A34K151E/A36-YFP CEV displayed polar A36
distribution and the majority of A36YdF-YFP and A34K151E/
A36YdF-YFP CEV displayed a circular A36 distribution, colocalis-
ing with extracellular B5 (Figure 6A, 6B). Collectively these data
show that in backgrounds that support actin-based motility,
introduction of the YdF mutation leads to viruses getting trapped
at the cell membrane with a failure to readily disengage virus–host
contact.
Discussion
The release of enveloped virus during VACV replication
Substantial evidence supports the critical role of the enveloped
form of orthopox viruses in cell-to-cell transmission [52,53],
despite EEV being stoichiometrically the minor infectious form
produced during virus replication [54,55]. Epitopes derived from
envelope proteins are major antigens recognised by host immune
defences and neutralising antibodies to these antigens are effective
in providing protective immunity [56,57]. Mutations in viral genes
that encode envelope-specific proteins also lead to attenuation
both in vitro, such as reduced cell-to-cell spread measured through
plaque assays, and when used to infect animal models [8,14].
These findings can be explained by effects on transmission by
CEV or the speed at which EEV are released from infected cells.
While there is evidence that both IMV and IEV are transported to
the cell periphery on microtubules, enveloped virus, using A36-
mediated transport via kinesin-1, is efficiently translocated to the
cell periphery at approximately eight hours post infection. This is
the earliest time point that infectious progeny are released [39,58]
and at this time relatively few IMV are dispersed throughout the
cell. Additionally, IMV lack a specific mechanism for release from
infected cells other than through cell lysis, which occurs only late
during infection [56]. Little is known regarding the fusion event
between the outer IEV envelope and the plasma membrane
leading to the formation of CEV, but this event correlates with a
number of changes at the molecular level. These changes include
the rapid dissociation of the viral proteins F12 and E2 and the
kinesin-1 motor complex [22,30,59,60], followed by recruitment of
Src- and Abl-family kinases and the phosphorylation of A36
[19,20,27,30]. Although the exact mechanism that leads to the
recruitment of cellular kinases to CEV is unknown, it is dependent
on an intact SCR4 domain of B5 which becomes exposed on the
cell surface upon viral fusion [30]. During super-repulsion, the B5
SCR4 must also be present on the surface of EEV to efficiently
induce actin-based motility on A33/A36 expressing cells [44].
This provides further support for the ability of this domain to
induce signalling events across the extracellular space between
enveloped virus and the plasma membrane. We have now shown
that in the absence of A36 phosphorylation and subsequent
localised actin nucleation, CEV remain trapped in pits at the
plasma membrane thereby blocking the liberation of EEV from
infected cells (Figure 6D). Our model is supported by the strong
inhibition in EEV release observed in the A36YdF strain, which can
be replicated through blocking actin nucleation by removing Nck
or with drug intervention.
Humphries et al. [61] have recently described a role for clathrin
and the clathrin adaptor protein AP-2 in the regulation of VACV-
induced actin nucleation. In the absence of AP-2, actin-based
motility is delayed and N-WASP turnover during motility is
reduced. Concurrent with these effects was a reduction in A36
polarisation, which strongly supports our findings: disrupting actin
nucleation correlates with inhibition of the expulsion of enveloped
virus at the cell surface. Even slight differences in the potential of
actin nucleation, such as between the A36Y112F and A36YdF
strains, results in changes to the efficiency of EEV release.
Humphries et al. also describe the localisation of N-Wasp, which,
like A36, is less polarised when actin nucleation is disrupted,
although the temporal dynamics in relation to virus expulsion are
not clear, as they were unable to distinguish between extracellular
and intracellular virus. With great prescience, Payne [15], upon
observing electron micrographs of Cyt D-treated IHD-J infected
cells, speculated that ‘‘the final separation of EEV from the plasma
membrane is probably dependent on functioning microfilaments
[actin]’’ but, as actin-based motility was unknown at the time,
concluded that the membrane dynamics associated with cell
motility was the ultimate cause.
Inhibiting the action of Abl-family kinases with the specific
inhibitor imatinib leads to a reduction in EEV release, implicating
these kinases in the regulation of this process. Despite our previous
work demonstrating that A36 was a direct Abl substrate [20], we
believe the mechanism by which imatinib disrupts virus release is
independent of the role of A36 based on the following evidence.
Firstly, disruption of Y112 and Y132 (A36YdF) leads to a far
stronger reduction in EEV (10-fold) than treatment with imatinib
(3-fold). Secondly, imatinib inhibits EEV release regardless of the
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integrity of A36 Y112 and Y132 residues. Therefore, while Abl
family kinases may regulate EEV release through phosphorylation
of A36, they do so redundantly with Src-family kinases, as we have
previously proposed for actin-based motility [20]. The effects of
imatinib on virus release suggests another, Src-independent, role
for Abl kinases, the mechanism of which remains unknown.
Tethering function of envelope proteins
To better characterise the mechanism by which actin nucleation
promotes virus release, we examined the effects of recombining the
A36YdF mutation into high EEV release backgrounds. These
included strains carrying mutations in the envelope proteins B5
(B5P189S) and A34 (A34K151E). The B5P189S virus exhibits high
levels of EEV release irrespective of the status of A36 Y112 and
Y132 residues [6,13,14]. In contrast, the high level of A34K151E
EEV release was potently suppressed by the A36YdF mutation.
These data show that in strains that activate actin-based motility
(WR and A34K151E) the YdF mutation suppresses EEV release,
but has no effect in cases where actin-based motility is absent
(B5P189S-infected or Nck null cells) [13,14,30]. Although both
A34K151E and B5P189S result in high levels of EEV, only the latter
bypasses the requirement for actin-based motility to facilitate
release. A34K151E appears to exhibit a faster rate of enveloped
virus production, but EEV release is nonetheless regulated in the
same manner as the parental WR strain [62]. In B5P189S a high
rate of EEV release is achieved at a cost to morphogenesis, hence
the small plaque phenotype. Collectively, these findings indicate
that two pathways can liberate EEV from the surface of cells:
localised actin filament nucleation or disruption of viral protein-to-
host membrane interactions. The exact nature of these interac-
tions is unclear as few experiments have been performed that are
able to distinguish between interactions occurring in cis and trans in
the viral envelope [63,64], and the pleiotropic roles of these
proteins confounds the interpretation of mutant phenotypes. The
best evidence for an interaction between the outer viral
membranes being mediated by the luminal domains of viral
proteins derives from Perdiguero et al. [65], who show that the
SCR regions of B5 can interact with the ectodomain of A34 in the
absence of transmembrane domains. Recent findings on the
mechanism of super-repulsion also implicate A33 as a B5-
interaction partner. Doceul et al [32] demonstrated that expression
of only A33 and A36 in the recipient host cell membrane is
required for super-repulsion. It was subsequently reported that the
B5P189S mutation on the surface of EEV also disrupts super-
repulsion actin-based motility [44]. Recently, an interaction was
identified between the isolated luminal domain of A33 and a
luminal coiled-coiled domain of B5 that lies adjacent to SCR4
[63]. As this interaction is dependent on the coiled-coiled domain
being anchored to a membrane, its role in adhesion across the viral
envelope membranes is unclear and may represent an indepen-
dent role for A33 in incorporation of B5 into the envelope, or vice
versa [63,64,65]. Intriguingly, mutations that increase B5–A33
adhesion result in reduced binding of EEV to host cells suggesting
a cis interaction in the membrane between these proteins and
raising the possibility that A33 might mask and/or regulate the
availability of the adjacent SCR4 [66]. Further characterisation of
the nature of these interactions may clarify how adhesion between
the outer viral membranes is achieved and regulated. In most
cases, a trade-off exists between adhesion and efficient wrapping as
a subset of high release mutations in envelope proteins result in
small plaque phenotypes and these viruses are attenuated when
used to infect mice (B5, A33 [8,13]). Disrupting these interactions
via the force of localised actin nucleation offers an elegant solution
to unshackling the luminal interactions that, while required for
efficient wrapping, need to be released for EEV to be untethered.
What is the role of EEV release during pathogenesis? The
literature does not offer a clear consensus as to whether strains that
release more EEV are more or less virulent. Mutations isolated in
a WR background such as B5P189S and A33 C-terminal
truncations lead to increased EEV release but also a reduction
in plaque size [13]. Unsurprisingly, viruses carrying these
mutations are attenuated when used to infect mice [13].
Alternatively, one can compare orthopox isolates with character-
istic EEV release profiles and correlate virulence. A comparison of
variola virus strains identified a high correlation between
decreased virulence and high EEV release [67]. It has been
speculated that the decreased virulence of the high release
orthopox strains may facilitate transmission between hosts to the
detriment of cell-to-cell transmission within a host [67]. Mice
infected with the high-release IHD-J strain, which carries the
A34K151 allele, display reduced mortality compared to those
infected with WR (70% verses 85% lethality over 3 weeks post-
infection) [52,54]. However, WR, which has low EEV release,
may be the exception rather than the rule; a broader comparison
of VACV strains show a positive correlation between EEV release
and the ability of the virus to disseminate within a host and cause
lethality [54]. All of these studies are limited by the use of animals
that have not been verified as a natural host and may therefore not
preserve aspects of endemic host–pathogen interactions during in
vivo spread and transmission.
Viral-induced F-actin nucleation
The first virus characterised as capable of undergoing actin-
based motility was VACV, but its role in enhancing infection
outcomes has only recently become clear. Virus plaques formed by
A36YdF are reduced in size, attesting to the role of these residues in
enhancing cell-to-cell spread ([36], this study) and enabling super-
repulsion [32]. Here we show that inhibition of A36-induced actin
nucleation results in a severe reduction in the release of infectious
EEV from infected cells, measured by liquid plaque assay or
directly quantified. It should not be surprising that once poxviruses
evolved a mechanism to exploit host actin dynamics, this
mechanism might be co-opted for other functions. For example,
localised actin nucleation may have evolved to untether EEV and
then subsequently have been exploited to mediate super-repulsion,
or vice versa. In principle, the direction of the co-opting of
function could be discriminated by the examination of the
promoter activity of A36R homologues; if actin nucleation evolved
to facilitate EEV release then distantly related homologues might
be expected to lack early stage transcriptional activity. Although
Figure 5. Redistribution of A36 during virus exit. (A) 3D-SIM fluorescent micrograph of A36-YFP/B5-RFP infected BSC-1 cell. Virus particles
associated with F-actin (red, left panel; visualised with Lifeact-cerulean) show polarisation of A36 (green) whereas B5 (red, right panel) localises to the
CEV circumference (close-ups). 3D-SIM fluorescent micrographs of (B) A36-YFP, (C) A36YdF-YFP in non-permeabilised BSC-1 cells probed with rat anti-
B5 primary antibody and Alexafluor 568 anti-rat secondary antibody. Close-ups show A36 (green) localisation in two representative intracellular (no
B5 visible) and extracellular virus particles. (D) 3D-SIM fluorescent micrographs of representative intracellular and extracellular B5P189S/A36-YFP,
B5P189S/A36YdF-YFP, A34K151E/A36-YFP or A34K151E/A36YdF-YFP viruses in non-permeabilised BSC-1 cells probed with rat anti-B5 primary antibody and
Alexafluor 568 anti-rat secondary antibody. All close-ups from larger panels are arranged in order from top to bottom. Scale bar = 5 mm.
doi:10.1371/journal.ppat.1003239.g005
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A36 is not highly conserved at the sequence level within the
Chordopoxvirinae subfamily, it is at the functional level. For example,
a diversity of poxviruses encode proteins at a homologous locus
that are able to restore actin-based motility in a VACV DA36
strain despite exhibiting as little as 9% homology at the amino acid
level [68]. Owing to the broad definition of early and late
promoter consensus motifs [69,70], a preliminary inspection to
identify the type of promoters in the A36R homologues was
Figure 6. Quantification of polarisation of A36. (A) Examples of the three categories for A36 distribution in 3D-SIM images: P = Polarised;
I = Intermediate; C =Circular, and (B) percentage of viruses in each category for cells infected with A36-YFP, A36YdF-YFP, B5P189S/A36-YFP, B5P189S/
A36YdF-YFP, A34K151E/A36-YFP or A34K151E/A36YdF-YFP. (C) Z-slices of representative A36 distributions in single A36-YFP and A36YdF-YFP virus
particles. Scale bars = 0.5 mm. (D) Schematic of proposed events at the cell membrane for WR, A36YdF, B5P189S or A34K151E during egress.
doi:10.1371/journal.ppat.1003239.g006
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unsuccessful. Functional studies of the activities of these promoters
would potentially resolve this issue. Future research may identify yet
further functions for VACV-induced actin nucleation in facilitating
virus spread. Pathogen-induced actin nucleation has evolved
independently in a number of viral and bacterial lineages, but the
role of actin nucleation in pathogenesis varies substantially [71,72].
During the colonisation of the intestinal tract by Enteropathogenic
Escherichia coli, extracellular bacteria are thought to attach to the
epithelium by the formation of F-actin-rich pedestals, utilising a
cascade bearing remarkable similarity to VACV-induced actin
nucleation [73]. Listeria monocytogenes stimulates polarised actin
nucleation at the surface of intracellular bacteria promoting motility
within the cell and forming long membrane extensions that may
enhance infection of neighbouring cells [74]. Similar structures are
observed in VACV infected cells, albeit tipped by an extracellular
pathogen, and these are likely to also facilitate cell-to-cell spread
during VACV infection. Herpesviruses must also resolve the
untethering luminal interactions during de-envelopment from the
nuclear membrane and exit at the plasma membrane. Although
very little is know regarding these processes there are remarkable
similarities to VACV escape [4]. Whether herpesvirus and VACV
have evolved similar mechanisms to release virus particles must
await further studies, currently F-actin has not been localised to
herpesvirus particles during release [75].
A close parallel to the role of actin nucleation that we describe
here for EEV release may be clathrin-mediated endocytosis. Here
actin filament nucleation at the neck of endocytic vesicles exhibits
sufficient force to promote internalisation and membrane scission
[76]. This pathway is used during influenza virus entry, which is
also sensitive to Cyt D [77]. Vaccinia virus EEV release operates
in reverse, the nucleator is localised to the intracellular cargo and
the force of actin nucleation peels away the outer envelope,
expelling the virus particle to the surface of the cell. Thus a similar
intermediate, a recently internalised influenza virus particle or a
recently egressed VACV CEV, will resolve in opposite directions
depending on where the force is applied.
Materials and Methods
Cells
African green monkey kidney cells (BSC-1), murine embryonic
fibroblasts (NIH3T3) and Nck-null NIH3T3 cells were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen)
supplemented with 5% foetal bovine serum (FBS), 292 mg/ml L-
glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin
(DMEM-FPSG) at 37uC and 5% CO2.
Viruses
Vaccinia virus strain Western Reserve (WR) and the mutant
viruses A36YdF, A36Y112F, A36Y132F and B5-YFP have been
described previously [26,59]. A36-YFP, A36YdF-YFP, A36-YFP/
B5-mRFP, B5P189S, B5P189S/A36YdF, A34K151E and A34K151E/
A36YdF, A36YdF/B5-YFP and A36Y112F/B5-YFP were prepared
as described previously [28,59,78,79]. Briefly, plasmids containing
recombination cassettes with either the point mutations or
fluorescent protein sequences flanked by left and right arm regions
homologous to the desired area of insertion were prepared. BSC-1
cells were infected with VACV WR and transfected with the
relevant vector using Lipofectamine (Invitrogen), as described by
the manufacturer, for production of A36-YFP, A36YdF-YFP,
B5P189S and A34K151E, or infected with A36YdF or A36Y112F and
transfected with the relevant vector for production of B5P189S/
A36YdF, A34K151E/A36YdF, A36YdF/B5-YFP and A36Y112F/B5-
YFP. For the other fluorescent viruses, BSC-1 cells were infected
with A36-YFP and transfected with the relevant vector for
production of A36-YFP/B5-mRFP, B5P189S/A36-YFP and
A34K151E/A36-YFP, or infected with B5P189S or A34K151E and
transfected with the A36YdF-YFP vector to produce B5P189S/
A36YdF-YFP and A34K151E/A36YdF-YFP, respectively. At
24 hours post infection (hpi) cells were scraped and recombinant
viruses purified by three rounds of plaque purification. Insertion at
the correct locus and correct sequence was confirmed by PCR and
sequencing.
Plaque and comet assays
BSC-1 or NIH3T3 cells were seeded in six-well plates and
grown to confluence. The virus strains were diluted in serum free
DMEM (SFM) and approximately 25 PFU was added to each
well. After incubation at 37uC in 5% CO2 for 1 h, the cells were
washed twice and overlaid with either 1.5% carboxymethyl
cellulose (CMC) in minimal essential medium (MEM) containing
2.5% FBS, 292 mg/ml L-glutamine, 100 units/ml penicillin and
100 mg/mL streptomycin for plaque assays, or DMEM-FPSG for
comet assays. For experiments with imatinib treatment, imatinib
mesylate (ChemiTek) at a final concentration of 10 mM or 0.01%
of the carrier, DMSO, was included in the overlay. Cells were
incubated for 3 days and then the overlay removed and cells
stained with 1% crystal violet in methanol for visualisation.
Single-step growth curves
BSC-1 cells were seeded into 12-well dishes, and confluent
monolayers were infected with either WR, A36YdF, A36Y112F or
A36Y132F in triplicate at a multiplicity of infection (MOI) of 5 for
1 h. The inoculum was removed, and the cell monolayer was
washed three times with PBS. Cells and supernatant were collected
at various times post-infection (4, 8, 12 and 24 h), freeze-thawed
three times and the virus concentration determined by plaque
assay of 10-fold serial dilutions in triplicate on BSC-1 cells. Cells
were incubated for 3 days and then the overlay removed and cells
stained with 1% crystal violet in methanol for visualisation.
EEV assay
12-well dishes were seeded with BSC-1 or NIH3T3 cells and
incubated with VACV strains (in triplicate) at an MOI of 0.1 for
1 h. Cells were then washed twice with PBS and DMEM-FPSG
was added. For inhibitor treatments, imatinib mesylate at a final
concentration of 10 mM, Cytochalasin D (Sigma-Aldrich) at a final
concentration of 0.1 mg/ml or 0.01% of the carrier, DMSO, was
added to the overlay media. The supernatants were collected at 16
hpi. To quantify the infectious EEV, plaque assays of 10-fold serial
dilutions of the supernatant were performed on BSC-1 cells as
described above. After 3 days cells were stained with methanol/
1% crystal violet and plaques enumerated. All EEV assays were
performed on at least three separate occasions.
Electron microscopy
Confluent monolayers of BSC-1 cells were infected at an MOI
of 5 and processed for TEM at 9 hpi. Briefly, cells were rinsed
twice with PBS and fixed with 1.5% glutaraldehyde in Na-
cacodylate buffer (0.1 M and 0.1 M sucrose) at pH 7.4 for 1 h.
The samples were subsequently washed with PBS and postfixed
with 1% osmium tetroxide in 0.1 M Na-cacodylate at pH 7.4 for
1 h. The cells were next dehydrated in a graded ethanol series.
After dehydration, samples were embedded in Epon and after
hardening of the embedding medium, the plastic of the multiwell
dishes was removed using liquid nitrogen. Sections of 120 nm
under various angles were cut with a diamond knife, stained first
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with uranyl acetate, subsequently with lead citrate, and examined
in a Jeol 2100 (Jeol, Tokyo, Japan) at 200 kV.
Fluorescent microscopy
BSC-1 cells were grown to 80% confluency on glass coverslips
and infected with WR, A36Y112 and A36YdF and fixed 8 hpi with
3% paraformaldehyde (PFA) in cytoskeletal buffer (CB) [10 mM 2-
(N-morpholino) ethanesulfonic acid (MES) buffer, 0.15 M NaCl,
5 mM ethylene glycol tetraacetic acid (EGTA), 5 mM MgCl2,
50 mM glucose, pH 6.1] for 10 minutes at room temperature.
Cells were blocked in blocking buffer (1% BSA, 2% FBS in CB) for
20 minutes then incubated for 40 minutes with 19C2 rat anti-B5
primary antibody (1/300) [80]. After three washes with PBS cells
were incubated with AlexaFluor568 (Invitrogen) anti-rat second-
ary antibody (1/200) and AlexaFluor488 Phalloidin for 20 min-
utes. The coverslips were mounted on a glass slide with 0.3–1%
(w/v) P-phenylenediamine (PPD; Sigma-Aldrich) in mowiol
mounting media [10% (w/v) Polyvinyl Alcohol 4–88 (Sigma-
Aldrich), 25% (w/v) glycerol, 0.1 M Tris, pH 8.5] and imaged
with an Olympus microscope BX51 with filter sets 31001, 31002
and 31013v2 (Chroma). The resulting images analysed with
Photoshop CS3 (Adobe).
For 3D-SIM, BSC-1 cells grown to 80% confluency on glass
coverslips were infected with the fluorescently-tagged viruses at an
MOI of 1. Transfection with plasmids expressing Lifeact-cerulean
[79] was performed using Lipofectamine (Invitrogen), as described by
themanufacturer. Cells were fixed at 8 hpi with 3%PFA for 10 min at
RT then washed with PBS. If required, cells were blocked with
blocking buffer and then probed with 19C2 rat anti-B5 primary
antibody (1/300) and AlexaFluor568 anti-rat secondary antibody (1/
200), diluted in the blocking buffer. The coverslips were mounted on a
glass slide with 0.3–1% PPD in mowiol mounting media. Imaging was
performed using a DeltaVision OMX 3D Structured Illumination
Microscopy System (OMX3D-SIM, Applied Precision Inc., Issaquah,
USA), as described previously [81,82]. General image handling was
undertaken with either Image J or Adobe Photoshop CS4.
Confocal microscopy
HeLa cells at 80% confluency were grown on Ibidi glass bottom
m-Dishes coated in fibronectin (5 mg/cm2, Sigma-Aldrich). Cells
were infected with B5-YFP, A36YdF/B5-YFP or A36Y112F/B5-
YFP and transfected with pE/L Lifeact-mRFP (Lipofectamine-
2000, Invitrogen) [79]. Immediately prior to imaging on Olympus
FV1000 confocal microscope at 6–9 hours post infection, media
was changed to Lebovitz’s L-15 (Invitrogen) with 5% FBS. Cells
showing distinct viral B5-YFP localisations and the appearance of
defined actin structures were imaged for 60 frames over 2 mins.
Images were analysed with Olympus Fluoview Viewer (Ver. 03.1)
and compiled with Adobe Photoshop CS4.
Analyses and statistics
Plaque diameters were measured using Image J. Differences in
EEV and plaque diameters were calculated using an unpaired t-
test with Prism 5.0 (Graph Pad Software) software. To determine
A36 distribution in 3D-SIM images, for each virus type 100 virus
particles selected from five representative cells were classified as
having polarised (P, less than 20% of virus circumference),
intermediate (I, 20–80% of virus circumference) or circular (C,
greater than 80% of virus circumference) A36 distribution (see
Figure 6A). Classification was performed double-blinded.
Supporting Information
Video S1 Live cell microscopy of VACV B5-YFP-induced actin
nucleation. HeLa cells were infected with B5R-YFP (green),
transfected with pE/L Lifeact-mRFP (red) and imaged for
80 seconds at 6–9 hours post infection. A virus particle is seen
colocalising with F-actin tail of approximately 3–4 mm. See
Figure 3D for still frames and representative scale bar.
(MOV)
Video S2 Live cell microscopy of VACV A36Y112F/B5-YFP-
induced actin nucleation. HeLa cells were infected with A36Y112F/
B5-YFP (green), transfected with pE/L Lifeact-mRFP (red) and
imaged for 80 seconds at 6–9 hours post infection. A virus particle
is seen undergoing rapid, presumably microtubule-dependent
motility, before pausing and nucleating F-actin. See Figure 3D for
still frames and representative scale bar.
(MOV)
Video S3 Live cell microscopy of VACV A36YdF/B5-YFP that
appears in one frame to colocalise with F-actin. HeLa cells were
infected with A36YdF/B5-YFP (green), transfected with pE/L Lifeact-
mRFP (red) and imaged for 80 seconds at 6–9 hours post infection.
Colocalisation between a virus particle and F-actin is observed
transiently at the beginning of themovie but is not associated with virus
motility. See Figure 3D for still frames and representative scale bar.
(MOV)
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